NCT Number: NCT00098228
Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.
Looking for future studies?
Notify MeKey information
Conditions
Age range
40 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
UAB Pulmonary Research, Birmingham, Alabama, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Diagnosis of COPD
- Age 40-75 years
- Smoking history
Exclusion criteria
- Other serious disease
- Allergy to QAB149
- Respiratory tract infection
Treatment and study plan
Primary outcomes
-
Pulmonary function measured between 22 and 24 hours after dosing on Day 1
Secondary outcomes
-
Pulmonary function measured on days 1 and 7 at various intervals after dosing
-
Safety measurements
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Novartis Pharmaceuticals
Industry
Registry information
Official study title
Dose-Ranging Study in Patients With COPD
Important dates
- Study start
- 2004
- Primary completion
- 2004
- Study completion
- 2004
- First posted
- Dec 6, 2004
- Registry last updated
- Oct 25, 2011
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
NCT04320342
COPD, COPD Exacerbation
Birmingham, Alabama, United States
View Trial DetailsEffect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure
NCT04522596
COPD, Cardiovascular Diseases
Madrid, Spain
View Trial DetailsEffect of Rehabilitation at Moderate Altitude on Airway Resistance Measured With Forced Oscillation Technique in COPD-patients
NCT07063563
Behavior, COPD
Bishkek, Kyrgyzstan
View Trial DetailsOxygen Therapy During Exercise Training in Inpatient Rehabilitation in Chronic Lung Disease- Does it Matter?
NCT07044843
Behavior, COPD
Bishkek, Kyrgyzstan
View Trial Details